Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

Area of Science:

• Orthopedic Surgery
• Pharmacology
• Vascular Medicine

Background:

• Thromboprophylaxis is crucial after hip replacement surgery.
• Low-molecular-weight heparins like enoxaparin are standard but have limitations.
• Oral direct factor Xa inhibitors offer potential advantages in efficacy and safety.

Purpose of the Study:

• To compare the efficacy and safety of apixaban versus enoxaparin for preventing venous thromboembolism (VTE) post-hip replacement.
• To evaluate the risk of bleeding associated with each anticoagulant regimen.

Main Methods:

• A double-blind, double-dummy randomized controlled trial involving 5407 patients undergoing hip replacement.
• Patients received either apixaban (2.5 mg twice daily) or enoxaparin (40 mg daily).
• Primary outcome was a composite of VTE or death; bleeding events were also assessed.

Main Results:

• Apixaban demonstrated superior efficacy, significantly reducing the primary composite outcome (1.4% vs. 3.9%, P<0.001).
• The incidence of major and clinically relevant nonmajor bleeding was similar between apixaban (4.8%) and enoxaparin (5.0%) groups.
• Absolute risk reduction for VTE with apixaban was 2.5 percentage points.

Conclusions:

• Apixaban is an effective thromboprophylaxis agent following hip replacement, showing lower rates of VTE than enoxaparin.
• The use of apixaban did not result in an increased risk of bleeding compared to enoxaparin.
• Apixaban offers a safe and effective oral alternative for VTE prevention in this patient population.